Ardelyx, Inc. - Common Stock (ARDX)

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Ardelyx (ARDX) stock surged 15% after Q3 2025 results, beating revenue estimates with strong growth from its drug IBSRELA and raising its full-year guidance.

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Ardelyx (ARDX) Q2 2025 earnings beat estimates with $97.7M revenue (+33% YoY) and -$0.08 EPS. Strong IBSRELA & XPHOZAH sales drove growth, sparking an 11.6% after-hours stock surge.

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.

Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.